论文部分内容阅读
目的:探讨血清降钙素原(PCT)水平变化对抗菌药物(替加环素与头孢哌酮-舒巴坦)治疗医院获得性肺炎(HAP)患者疗效的影响。方法:选取2012年4月—2015年5月间收治的HAP患者65例作为研究对象,按照随机数字表法将其分为A组(n=33)和B组(n=32);A组患者根据其血清PCT水平指导使用替加环素与头孢哌酮-舒巴坦联治疗,B组患者根据其临床结合影像学指导使用替加环素与头孢哌酮-舒巴坦联用治疗,比较两组患者治疗后的治愈时间、细菌清除率和复发率。结果:A组患者治疗后治愈时间明显短于B组(P<0.05),细菌清除率和复发率与B组间比较其差异均无统计学意义(P>0.05)。结论:血清PCT检测在指导替加环素与头孢哌酮-舒巴坦联用治疗HAP患者中具有较高的临床价值,可有效缩短治愈时间。
Objective: To investigate the effect of serum procalcitonin (PCT) levels on the curative effect of antimicrobial agents (tigecycline and cefoperazone-sulbactam) in patients with hospital acquired pneumonia (HAP). Methods: A total of 65 HAP patients admitted from April 2012 to May 2015 were selected as study subjects and divided into group A (n = 33) and group B (n = 32) according to the random number table method. Group A Patients according to their level of serum PCT guide the use of tigecycline and cefoperazone - sulbactam combined treatment, patients in group B according to their clinical and imaging guidelines using tigecycline combined with cefoperazone - sulbactam treatment, The healing time, bacterial clearance rate and recurrence rate were compared between the two groups after treatment. Results: The cure time of group A was significantly shorter than that of group B (P <0.05). There was no significant difference between group B and group B (P> 0.05). Conclusion: The serum PCT test has high clinical value in guiding the treatment of HAP patients with tigecycline and cefoperazone-sulbactam, which can shorten the cure time effectively.